Perigon Wealth Management LLC Acquires 1,968 Shares of Amgen Inc. $AMGN

Perigon Wealth Management LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,744 shares of the medical research company’s stock after buying an additional 1,968 shares during the period. Perigon Wealth Management LLC’s holdings in Amgen were worth $6,426,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Commerzbank Aktiengesellschaft FI raised its position in shares of Amgen by 7.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 209,478 shares of the medical research company’s stock worth $75,856,000 after acquiring an additional 14,693 shares in the last quarter. Trust Co. of Vermont bought a new stake in Amgen during the second quarter valued at about $8,236,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Amgen by 7.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,478,418 shares of the medical research company’s stock worth $535,365,000 after buying an additional 97,238 shares during the last quarter. Plato Investment Management Ltd grew its holdings in Amgen by 2.7% in the second quarter. Plato Investment Management Ltd now owns 22,412 shares of the medical research company’s stock worth $8,068,000 after purchasing an additional 599 shares during the last quarter. Finally, Hexagon Capital Partners LLC increased its position in shares of Amgen by 11.7% during the second quarter. Hexagon Capital Partners LLC now owns 1,308 shares of the medical research company’s stock worth $474,000 after purchasing an additional 137 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Up 1.4%

Shares of NASDAQ:AMGN opened at $425.28 on Wednesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $427.39. The stock has a market cap of $229.92 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 3.86 and a beta of 0.41. The business has a 50-day moving average price of $373.66 and a 200-day moving average price of $360.06.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the prior year, the firm earned $6.02 earnings per share. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Canaccord Genuity Group boosted their target price on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Mizuho boosted their price target on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday. Truist Financial increased their price objective on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. TD Cowen boosted their target price on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Daiwa Securities Group decreased their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $375.93.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent results reinforced its growth narrative: quarterly revenue rose 9.5% year over year to $10.05 billion, while adjusted earnings of $6.29 per share exceeded consensus by $0.67. Management’s fiscal 2026 EPS guidance of $22.30–$23.50 also supports the bullish outlook. Amgen Results Put Growth Back in Focus
• Positive Sentiment: A completed Phase 1 study comparing two evolocumab formulations provides continued support for Amgen’s cholesterol franchise. Evolocumab, marketed as Repatha, is an important commercial product, and formulation work could help support its future development and patient use. Amgen’s Evolocumab Formulation Study
• Positive Sentiment: Growth-focused analysis from Zacks highlights Amgen’s earnings profile and potential for continued performance, adding to the favorable investor narrative. Why Amgen Is a Strong Growth Stock
• Neutral Sentiment: Cantor Fitzgerald raised its Amgen price target to $400 but retained a Neutral rating. Mizuho also maintained Neutral while lifting its target to $352, indicating that analysts see some fundamental improvement but believe the recent rally has exceeded their valuation expectations.
• Negative Sentiment: Amgen exercised its right to terminate a partnership with TScan Therapeutics, removing a collaboration from TScan’s pipeline. While the direct financial effect on Amgen is unclear, the termination may raise questions about partnership prioritization or the development prospects of the related program. TScan Therapeutics Faces Loss of Key Amgen Partnership

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 in the last quarter. Company insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.